Skip to content
PeptideAgent

Clinics in Delaware

By the PeptideAgent Editorial Team. Draft, pending editorial review.  Last verified

What Delaware law means for peptide clinics: who may prescribe, whether pharmacies may compound GLP-1 drugs (limited), how to check a clinic, and verified listings.

Delaware at a glance

503A framework
Follows the federal 503A framework
Telehealth prescribing
Regulatory: Telehealth allowed
Asynchronous prescribing
Regulatory: Async allowed
Compounded GLP-1 access
Regulatory: Compounded GLP-1 limited

Verified clinics serving Delaware

No verified clinics serving Delaware are listed yet. A provider appears here only after it passes the verification checklist, and those checks are still under way.

Looking for care now? Start with what the law allows where you live, then how a legitimate prescription works.

Run a pharmacy, clinic, or telehealth service? Apply for a listing.

Peptide access rules in Delaware

Yes. A Delaware resident can obtain FDA approved peptides such as semaglutide and tirzepatide by prescription through telehealth under Title 24, chapter 60 of the Delaware Code, from a Delaware-licensed provider or from an out-of-state physician who holds a Delaware interstate telehealth registration. Compounded peptides are available when eligible under federal 503A rules and dispensed by a Delaware pharmacy or a pharmacy holding a Delaware nonresident pharmacy license (24 Del. C. 2535 through 2537), which must send the Delaware Board of Pharmacy its home-state inspection reports. Delaware bars prescribing solely from an internet questionnaire when no provider-patient relationship exists. [1] [2] [3] [4] [5] [6] [7] [9]

Compounded GLP-1 access in Delaware

Delaware patients using an out-of-state telehealth GLP-1 program should confirm the prescriber is Delaware-licensed or holds an interstate telehealth registration, and that the pharmacy holds a Delaware nonresident pharmacy license. [4] [6] [10]

Research use only sellers in Delaware

Only Delaware-licensed pharmacies and licensed nonresident pharmacies may dispense prescription drugs to Delaware patients. "Research use only" peptides sold for human injection are unapproved new drugs under federal law, are not dispensed by a pharmacist, and fall outside Delaware's pharmacy licensing system. Delaware's own food and drug law (16 Del. C. chapter 33, Pure Food and Drugs) prohibits manufacturing or selling an adulterated or misbranded drug (section 3302) but has no separate new-drug approval provision, so the prohibition on selling unapproved new drugs comes from federal law. [6] [8] [11]

Delaware notes on specific peptides

  • Semaglutide: Available branded by prescription through telehealth under 24 Del. C. chapter 60, including from out-of-state physicians with a Delaware interstate telehealth registration. Compounded semaglutide is limited to documented patient-specific needs since the 503A grace period ended April 22, 2025. [2] [4] [10]

How to check a clinic in Delaware

  1. Confirm the prescribing clinician's license with the Delaware medical or nursing board.
  2. Ask which pharmacy compounds or dispenses the peptide and check it in the Delaware Board of Pharmacy (Division of Professional Regulation) license lookup. [1] [5] [6] [7] [9]
  3. Confirm the peptide can be lawfully compounded: check its status on the regulatory tracker or its peptide page before paying.
  4. Walk away from any seller that labels a peptide "research use only" or "not for human consumption". See the research use only section above for what that means in Delaware. [6] [8] [11]

Common questions in Delaware

Can an out-of-state telehealth doctor prescribe me a GLP-1 in Delaware?

Yes, if the physician holds a Delaware license or a Delaware interstate telehealth registration. The Division of Professional Regulation issues these registrations to physicians licensed in good standing in another state, and the provider must still establish a provider-patient relationship under 24 Del. C. 6003. [3] [4]

Can I get a prescription in Delaware just by filling out an online form?

Not without a proper provider-patient relationship. Section 6003 bars issuing a prescription solely in response to an internet questionnaire, internet consult, or telephone consult when no relationship has been established, and the relationship requires identity and location verification and disclosure of the provider's credentials. [3]

All peptide legal questions for Delaware

Sources

  1. [1]Delaware Board of Pharmacy, Division of Professional Regulation
  2. [2]Delaware Code Title 24, chapter 60, Provisions applicable to telehealth and telemedicine
  3. [3]24 Del. C. 6003, Scope of practice; provider-patient relationship required
  4. [4]Delaware Division of Professional Regulation: medical interstate telehealth registrations
  5. [5]Delaware Code Title 24, chapter 25, Pharmacy
  6. [6]Delaware Code Title 24, chapter 25, subchapter IV, Pharmacies (nonresident pharmacy sections 2535 to 2537)
  7. [7]Delaware Administrative Code Title 24, 2500 Board of Pharmacy regulations (5.1.6 Compounding; 10.0 Pharmaceutical Compounding), accessed 2026-09-22
  8. [8]Delaware Code Title 16, chapter 33, Pure Food and Drugs (section 3302), accessed 2026-09-22
  9. [9]FDA: Section 503A of the Federal Food, Drug, and Cosmetic ActFDA
  10. [10]FDA: concerns with unapproved GLP-1 drugs used for weight loss, including shortage resolution and compounding grace periodsFDA
  11. [11]21 U.S.C. 331, Prohibited acts